Alagille Syndrome: Long-Term Study of Livmarli

We are examining the long-term safety and effectiveness of Livmarli in patients with Alagille Syndrome. This study will help us understand how well the treatment works and its tolerability over time.

>2 years Monitoring phase (IV)No Placebo Cost Reimbursement Investigational Medicines OralCardiologyHepatologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Maralixibat

Maralixibat is a substance that lowers bile acids to help relieve severe itching from liver-related bile buildup.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Livmarli

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Universitair Ziekenhuis Gent

Pediatric Gastroenterology Department

Ledeberg, Belgium

Cliniques Universitaires Saint-Luc

Pediatric Department

Sint-Stevens-Woluwe, Belgium

Hopital Des Enfants

Gastro-entérologie, hépatologie, nutrition et maladies héréditaires du métabolisme

Blagnac, France

Sponsor: Mirum Pharmaceuticals Inc.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.